[Immunogenicity of the Heberbiovac-HB vaccine in the physically and mentally handicapped].
The recombinant DNA Heberbiovac-HB vaccine against hepatitis B was applied to 2 groups of children at 2 homes for the physically and mental disabled at doses of 10 and 5 micrograms with the scheme 0, 1 and 6 months to study its immunogenicity, which was evaluated at 2, 7 and 12 months after the first dose was administered. On the 60th day it was obtained 80.9% of seroprotection in children who received 10 micrograms, whereas in the group that was vaccinated with 5 micrograms 65.0% of seroprotection was attained and there were no significant differences between the groups. 100% of seroprotection (> or = 10 UI/L) was obtained in the 2 vaccinated groups when the immune response was measured 1 month after the third dose was applied. A year later, seroprotection was 100% for the 2 groups of children. The geometrical mean of the antibody titres (TMG) reached levels above 10 UI/L, which is the minimum protector, in the 2 study groups 30 days after the second dose. A month after the third dose, the TMG attained values of 527.7 UI/L in the group of 10 micrograms and of 324.7 UI/L in that of 5 micrograms. No remarkable differences were found between the groups (p < 0.05). Finally, 365 days later, the TMG descended to 139.7 UI/L and 57.3 UI/L in the same groups, respectively. It was demonstrated the high immunogenic power of this vaccine, which makes it recommendable for protecting the physical and mentally disabled children from hepatitis B virus.
Instituto de Medicina Tropical Pedro Kourí.
P
P
Pedroso Flaquet
M
M
Díaz González
L
L
Rodríguez Lay
J R
JR
Bravo González
D000293:Adolescent; D002648:Child; D002674:Child, Institutionalized; D006233:Persons with Disabilities; D004306:Dose-Response Relationship, Immunologic; D005069:Evaluation Studies as Topic; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000096:biosynthesis* / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic